PFM
ENGN icon

Privium Fund Management’s enGene Therapeutics ENGN Stock Holding History

Privium Fund Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Sell
170,000
-182,087
-52% -$742K 0.05% 60
2026
Q1 		$2.4M Hold
352,087
– – 0.5% 32
2025
Q4 		$3.18M Buy
+352,087
New +$2.82M 0.59% 26

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Privium Fund Management's ENGN Position: Q2 2026 in Review

Privium Fund Management reduced its enGene Therapeutics (ENGN) stake by 52% in Q2 2026, selling an estimated $742K and leaving 170,000 shares worth $294K. The position accounts for 0.05% of the portfolio, ranked #60.

Privium Fund Management first reported a position in ENGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.18M in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Privium Fund Management held 170,000 shares of enGene Therapeutics worth $294K as of Q2 2026.
  • Privium Fund Management sold 182,087 enGene Therapeutics shares in Q2 2026, an estimated $742K.
  • enGene Therapeutics made up 0.05% of Privium Fund Management's portfolio in Q2 2026, its #60 holding.
  • Privium Fund Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Privium Fund Management's enGene Therapeutics position peaked at $3.18M in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.